168 related articles for article (PubMed ID: 23729024)
1. Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.
Das S; Pandey K; Rabidas VN; Mandal A; Das P
J Antimicrob Chemother; 2013 Sep; 68(9):2059-65. PubMed ID: 23729024
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
3. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
4. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
Mishra J; Singh S
Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
Mukhopadhyay D; Das NK; Roy S; Kundu S; Barbhuiya JN; Chatterjee M
J Infect Dis; 2011 Nov; 204(9):1427-36. PubMed ID: 21933878
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.
Mukherjee AK; Gupta G; Adhikari A; Majumder S; Kar Mahapatra S; Bhattacharyya Majumdar S; Majumdar S
Int Immunopharmacol; 2012 Apr; 12(4):565-72. PubMed ID: 22361489
[TBL] [Abstract][Full Text] [Related]
8. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
9. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection.
Bhattacharjee S; Bhattacharjee A; Majumder S; Majumdar SB; Majumdar S
J Antimicrob Chemother; 2012 Aug; 67(8):1905-14. PubMed ID: 22589456
[TBL] [Abstract][Full Text] [Related]
11. Hepatoprotective effect of lucidone against alcohol-induced oxidative stress in human hepatic HepG2 cells through the up-regulation of HO-1/Nrf-2 antioxidant genes.
Senthil Kumar KJ; Liao JW; Xiao JH; Gokila Vani M; Wang SY
Toxicol In Vitro; 2012 Aug; 26(5):700-8. PubMed ID: 22484158
[TBL] [Abstract][Full Text] [Related]
12. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Shakya N; Sane SA; Vishwakarma P; Gupta S
Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
[TBL] [Abstract][Full Text] [Related]
13. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
Das S; Rani M; Rabidas V; Pandey K; Sahoo GC; Das P
Br J Pharmacol; 2014 Mar; 171(5):1260-74. PubMed ID: 24670148
[TBL] [Abstract][Full Text] [Related]
14. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
Shivahare R; Vishwakarma P; Parmar N; Yadav PK; Haq W; Srivastava M; Gupta S; Kar S
PLoS One; 2014; 9(4):e94596. PubMed ID: 24732039
[TBL] [Abstract][Full Text] [Related]
15. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
16. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
[TBL] [Abstract][Full Text] [Related]
17. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
[TBL] [Abstract][Full Text] [Related]
19. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
[TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.
Yadav A; Amit A; Chaudhary R; Chandel AS; Mahantesh V; Suman SS; Singh SK; Dikhit MR; Ali V; Rabidas V; Pandey K; Kumar A; Das P; Bimal S
Int J Parasitol; 2015 Jan; 45(1):33-42. PubMed ID: 25449949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
